Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...

Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...

Bridging academic and community oncology requires formal communication pathways, shared education/research infrastructure, ...

In 2021, a woman with severe lupus at University Hospital Erlangen in Germany became the first person to receive CAR-T cell ...

Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris’ Target Profile, ...

For decades, scientists understood inducible nitric oxide synthase, or iNOS, as a one-trick enzyme. Its job was to churn out ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based cancer therapy. Helper T cells act as the immune system’s coordinators, helping ...

This manuscript has convincing data that provides a high-resolution structure of the Egl-RNA complex. The findings are important to understand the formation, stability, and interactions of this ...

FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...